21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein?

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          The distinctive pathological hallmarks of Parkinson's disease are the progressive death of dopaminergic neurons and the intracellular accumulation of Lewy bodies enriched in α-synuclein protein. Several lines of evidence from the study of sporadic, familial and pharmacologically induced forms of human Parkinson's disease also suggest that mitochondrial dysfunction plays an important role in disease progression. Although many functions have been proposed for α-synuclein, emerging data from human and animal models of Parkinson's disease highlight a role for α-synuclein in the control of neuronal mitochondrial dynamics. Here, we review the α-synuclein structural, biophysical and biochemical properties that influence relevant mitochondrial dynamic processes such as fusion-fission, transport and clearance. Drawing on current evidence, we propose that α-synuclein contributes to the mitochondrial defects that are associated with the pathology of this common and progressive neurodegenerative disease.

          Abstract

          Summary: The authors review the α-synuclein structural, biophysical and biochemical properties that influence relevant mitochondrial physiological processes such as fusion-fission, transport and clearance, and propose that α-synuclein contributes to the mitochondrial defects that are associated with Parkinson's disease.

          Related collections

          Most cited references100

          • Record: found
          • Abstract: found
          • Article: not found

          Stages in the development of Parkinson's disease-related pathology.

          The synucleinopathy, idiopathic Parkinson's disease, is a multisystem disorder that involves only a few predisposed nerve cell types in specific regions of the human nervous system. The intracerebral formation of abnormal proteinaceous Lewy bodies and Lewy neurites begins at defined induction sites and advances in a topographically predictable sequence. As the disease progresses, components of the autonomic, limbic, and somatomotor systems become particularly badly damaged. During presymptomatic stages 1-2, inclusion body pathology is confined to the medulla oblongata/pontine tegmentum and olfactory bulb/anterior olfactory nucleus. In stages 3-4, the substantia nigra and other nuclear grays of the midbrain and forebrain become the focus of initially slight and, then, severe pathological changes. At this point, most individuals probably cross the threshold to the symptomatic phase of the illness. In the end-stages 5-6, the process enters the mature neocortex, and the disease manifests itself in all of its clinical dimensions.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.

            Lewy bodies and Lewy neurites are the defining neuropathological characteristics of Parkinson's disease and dementia with Lewy bodies. They are made of abnormal filamentous assemblies of unknown composition. We show here that Lewy bodies and Lewy neurites from Parkinson's disease and dementia with Lewy bodies are stained strongly by antibodies directed against amino-terminal and carboxyl-terminal sequences of alpha-synuclein, showing the presence of full-length or close to full-length alpha-synuclein. The number of alpha-synuclein-stained structures exceeded that immunoreactive for ubiquitin, which is currently the most sensitive marker of Lewy bodies and Lewy neurites. Staining for alpha-synuclein thus will replace staining for ubiquitin as the preferred method for detecting Lewy bodies and Lewy neurites. We have isolated Lewy body filaments by a method used for the extraction of paired helical filaments from Alzheimer's disease brain. By immunoelectron microscopy, extracted filaments were labeled strongly by anti-alpha-synuclein antibodies. The morphologies of the 5- to 10-nm filaments and their staining characteristics suggest that extended alpha-synuclein molecules run parallel to the filament axis and that the filaments are polar structures. These findings indicate that alpha-synuclein forms the major filamentous component of Lewy bodies and Lewy neurites.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models.

              Alpha-synuclein (alphaSyn) misfolding is associated with several devastating neurodegenerative disorders, including Parkinson's disease (PD). In yeast cells and in neurons alphaSyn accumulation is cytotoxic, but little is known about its normal function or pathobiology. The earliest defect following alphaSyn expression in yeast was a block in endoplasmic reticulum (ER)-to-Golgi vesicular trafficking. In a genomewide screen, the largest class of toxicity modifiers were proteins functioning at this same step, including the Rab guanosine triphosphatase Ypt1p, which associated with cytoplasmic alphaSyn inclusions. Elevated expression of Rab1, the mammalian YPT1 homolog, protected against alphaSyn-induced dopaminergic neuron loss in animal models of PD. Thus, synucleinopathies may result from disruptions in basic cellular functions that interface with the unique biology of particular neurons to make them especially vulnerable.
                Bookmark

                Author and article information

                Journal
                Dis Model Mech
                Dis Model Mech
                DMM
                dmm
                Disease Models & Mechanisms
                The Company of Biologists Ltd
                1754-8403
                1754-8411
                1 September 2017
                1 September 2017
                : 10
                : 9
                : 1075-1087
                Affiliations
                [1 ]Instituto de Biología Celular y Neurociencias, IBCN (UBA-CONICET) , Facultad de Medicina, Universidad de Buenos Aires , Paraguay 2155, Buenos Aires, CP1121, Argentina
                [2 ]International Clinical Research Center (ICRC), St. Anne's University Hospital , CZ-65691, Brno, Czech Republic
                [3 ]Instituto de Biología y Medicina Experimental, IBYME-CONICET , Vuelta de Obligado 2490, Buenos Aires, CP1428, Argentina
                Author notes
                [* ]Author for correspondence ( tfalzone@ 123456fmed.uba.ar )
                Author information
                http://orcid.org/0000-0002-7984-1149
                Article
                DMM026294
                10.1242/dmm.026294
                5611962
                28883016
                6315fcb8-6003-4cb3-8c10-394ad26e1653
                © 2017. Published by The Company of Biologists Ltd

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

                History
                : 29 June 2017
                : 13 July 2017
                Funding
                Funded by: Agencia Nacional de Promoción Científica y Tecnológica, http://dx.doi.org/10.13039/501100003074;
                Award ID: PICT 2011-2027
                Award ID: PICT 2013-0402
                Funded by: Universidad de Buenos Aires, http://dx.doi.org/10.13039/501100005363;
                Award ID: UBACyT
                Funded by: Consejo Nacional de Investigaciones Científicas y Técnicas, http://dx.doi.org/10.13039/501100002923;
                Funded by: European Social Fund, http://dx.doi.org/10.13039/501100004895;
                Funded by: European Regional Development Fund, http://dx.doi.org/10.13039/501100008530;
                Award ID: CZ.02.1.01/0.0/0.0/ 15_003/0000492
                Funded by: Company of Biologists, http://dx.doi.org/10.13039/501100000522;
                Categories
                302
                Perspective

                Molecular medicine
                parkinson's disease,synuclein,mitochondria,fusion-fission,transport,mitophagy
                Molecular medicine
                parkinson's disease, synuclein, mitochondria, fusion-fission, transport, mitophagy

                Comments

                Comment on this article